Free Trial
NASDAQ:BMRA

Biomerica Q4 2026 Earnings Results & Report

Biomerica logo
$1.83 -0.06 (-3.17%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomerica beat analyst earnings expectations but missed on revenue in its Q4 2026 results, released August 31, 2026. The company reported EPS of -$0.38 versus the -$1.20 consensus estimate, while revenue of $0.88 million fell short of the $3.63 million estimate by $2.75 million.

Earnings Announcement Details

Quarter
Q4 2026
Report Date
Time
Before Market Opens

Biomerica EPS Results

Actual EPS
-$0.38
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$0.88 million
Expected Revenue
$3.63 million
Beat/Miss
Missed by -$2.75 million
YoY Revenue Growth
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026, based on past reporting schedules.

Conference Call Resources

Biomerica Q4 2026 Earnings FAQ

Biomerica (NASDAQ:BMRA) reported earnings of -$0.38 per share for Q4 2026, beating the consensus estimate of -$1.20. The report was announced on Monday, August 31, 2026.

Biomerica reported revenue of $0.88 million for Q4 2026, against a consensus estimate of $3.63 million.

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biomerica on the company's earnings history page.

Biomerica Earnings Headlines

Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
Biomerica Files $250 Million Mixed Shelf
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.

Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.

Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses. Its products have been distributed through healthcare providers and commercial partners in the United States and select international markets. The company is headquartered in Irvine, California, and has been led by Chief Executive Officer Zackary Irani.

View Biomerica Profile